Who are Vaxcyte, Inc.'s main suppliers?

Vaxcyte, Inc. (PCVX) key suppliers include: SUTRO-BIOPHARMA, LONZA, Thermo Fisher Scientific Inc., Thermo Fisher Scientific Inc., GSK plc and 7 more. View the full supplier network at chainsifter.com/chain/PCVX.

Who are Vaxcyte, Inc.'s major customers?

Vaxcyte, Inc. (PCVX) key customers include: Sanofi, Sanofi, Sutro Biopharma, Inc., Sutro Biopharma, Inc.. View the full customer network at chainsifter.com/chain/PCVX.

What sector is Vaxcyte, Inc. in?

Vaxcyte, Inc. (PCVX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

PCVX Supply Chain: Vaxcyte, Inc. Supplier List & 18 Relationships

12Suppliers

4Customers

2Debt Items

20Related Chains

Vaxcyte, Inc. Suppliers

Ticker	Name	Confidence	Evidence
SUTRO-BIOPHARMA	SUTRO-BIOPHARMA	92%	pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions utilizing the technology licen…
LONZA	LONZA	90%	Lonza will (i) construct and build out a dedicated suite (the "Suite") at Lonza's facilities in Visp, Switzerland to manufacture certain key components (including drug substance) for our proprietary …
TMO	Thermo Fisher Scientific Inc.	90%	Reciprocal relationship from TMO graph: Reciprocal relationship from PCVX graph: In September 2025, we also entered into a master services agreement with Patheon Manufacturing Services LLC, part of T…
TMO	Thermo Fisher Scientific Inc.	90%	In September 2025, we also entered into a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (collectively, “Thermo Fisher”), pursuant to which Thermo…
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from GSK grap…
GSK	GSK plc	72%	accines to prevent or treat serious infectious diseases. Key elements of our strategy include: • Advance our PCV candidates through clinical development and regulatory approval. Our PCV candidates, V…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from PCVX graph: accines to prevent or treat serious infectious diseases. Key elements of our strategy include: • Advance our PCV candi…
MRK	Merck & Co., Inc.	72%	accines to prevent or treat serious infectious diseases. Key elements of our strategy include: • Advance our PCV candidates through clinical development and regulatory approval. Our PCV candidates, V…
SNYNF	Sanofi	72%	cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the continued development and execution of global commercialization, including pre-laun…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the …
STRO	Sutro Biopharma, Inc.	72%	Reciprocal relationship from STRO graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from STRO graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from STRO g…
STRO	Sutro Biopharma, Inc.	72%	rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturing capacity to meet potential incremental…

Vaxcyte, Inc. Customers

Ticker	Name	Confidence	Evidence
SNYNF	Sanofi	72%	cs. As part of our strategy to prepare for future commercialization of our PCV programs, Mr. Mullette will lead the continued development and execution of global commercialization, including pre-laun…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from PCVX graph: cs. As part of our strategy to pr…
STRO	Sutro Biopharma, Inc.	72%	rrently expect or change their requirements regarding the data required to support a marketing application; • the costs of establishing additional manufacturing capacity to meet potential incremental…
STRO	Sutro Biopharma, Inc.	72%	Reciprocal relationship from STRO graph: Reciprocal relationship from PCVX graph: rrently expect or change their requirements regarding the data required to support a marketing application; • the cos…

Vaxcyte, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PCVX-DEBT	Debt stack $116.3M	90%	Market cache reports total debt of $116.3M.
PCVX-DEBT-11708	Warrants outstanding: 5463793	90%	xbrl warrant detail from xbrl 2026-03-31.

Vaxcyte, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vaxcyte, Inc..

Vaxcyte, Inc. Ownership

Holder	Name	Confidence	Evidence
PCVX-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 338 tracked holders.

Vaxcyte, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
EDIT	Editas Medicine, Inc.	100.00	2
FULC	Fulcrum Therapeutics, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
DEO	Diageo plc	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2

Vaxcyte, Inc. Supply Chain